Fundz

Watching GALECTIN THERAPEUTICS INC? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Material AgreementItem 1.01 · 8-KMEDIUM RiskMixed

GALECTIN THERAPEUTICS INC

galectintherapeutics.com
Filed: Jul 31, 2026Norcross, GeorgiaCIK: 0001359054Healthcare
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Galectin Therapeutics converted $81 million in outstanding convertible promissory notes into 34.4 million shares of common stock issued to Chairman Richard E. Uihlein on July 31, 2026, converting debt into equity and strengthening the company's capital structure.

Key Takeaways

Conversion of $81 million in debt obligations into equity eliminates significant debt burden and improves balance sheet leverage ratios

Issuance of 34.4 million shares to the Chairman represents substantial dilution to existing shareholders but consolidates credit facilities

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 31, 2026
Item1.01
CategoryMaterial Agreement
CIK0001359054
Accession #0001359054-26-000030
Risk LevelMEDIUM
SentimentMixed
Signalopportunity
Topics
debt financingstock offering

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings

GALECTIN THERAPEUTICS INC filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.